)
Visual
test
Biosyent
Biosyent (RX) investor relations material
Biosyent Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Mar, 2026
Executive summary
Achieved double-digit revenue and profit growth in Q4 and FY 2025, driven by Canadian pharma, international Tibelia, and legacy businesses.
Completed the acquisition of Oral Science Inc. in March 2026, expanding into oral health and diversifying revenue streams.
Maintained a consistent record of profitability, marking the 62nd consecutive profitable quarter.
Paid increased quarterly dividends and continued share buybacks, reflecting strong capital returns.
Continued investment in key brands and new product launches, supporting both Canadian and international growth.
Financial highlights
Q4 2025 revenue reached $9.7M (+10% YoY); FY 2025 revenue was $43.1M (+23% YoY).
Q4 2025 EBITDA was $2.53M (+13% YoY); FY 2025 EBITDA was $12.12M (+30% YoY).
Q4 2025 net income after tax was $1.99M (+23% YoY); FY 2025 net income was $9.01M (+24% YoY).
Fully diluted EPS for 2025 was $0.78, up from $0.62 in 2024 and $0.54 in 2023.
Gross profit for FY 2025 was $32.96M (+18% YoY), with a gross margin of 77%.
Outlook and guidance
Future results will include Oral Science, with one month consolidated in Q1 2026.
Dividend increased to $0.055 per share quarterly, projecting $0.22 per share for 2026.
Expectation to fully repay acquisition debt by end of Q3 2026.
Ongoing investment in pharmaceutical and oral health platforms to drive future growth.
Focus on expanding newly acquired oral health business and maintaining capital-light, cash-generating operations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biosyent
- Consistent profitability, innovation, and disciplined growth drive future expansion plans.RX
Planet MicroCap Showcase: VEGAS 20253 Feb 2026 - Record sales, profit, and margin growth in H1 2024, led by strong brands and innovation.RXQ2 202423 Jan 2026
- Sustained profitability and growth fueled by new products, acquisitions, and shareholder returns.RXLytham Partners Fall 2024 Investor Conference19 Jan 2026
- Record Q3 sales, strong cash, and Tibelia® acquisition set stage for future growth.RXQ3 202413 Jan 2026
- FY 2024 sales up 11%, net income up 13%, with strong margins and global expansion.RXQ4 202426 Dec 2025
- Record Q1 2025 sales, 42% revenue growth, strong margins, and $0.05 dividend declared.RXQ1 202525 Nov 2025
- Q2 2025 sales up 14%, profit and margins rose, with strong cash flow and shareholder returns.RXQ2 202523 Nov 2025
- Record sales and profit growth driven by key brands, strong margins, and capital returns.RXQ3 202521 Nov 2025
Next Biosyent earnings date
Q1 202614 May, 2026
Biosyent
Next Biosyent earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage